Erickson Living

ericksonliving.com

Erickson Living is the leading developer and manager of continuing care communities and home to 25,000 seniors across the United States. Each day, our 15,000 employees strive to provide the very best in care and service to the residents who choose to call us home. With first rate amenities and programs delivered in vibrant campus settings, Erickson Living is setting a new standard of senior health and wellness.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

news image

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

news image

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More
news image

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More
news image

Cell and Gene Therapy

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More
news image

Industrial Impact

PSYCHECEUTICAL COMPLETES ACQUISITION BY BLUE WATER VENTURES INTERNATIONAL

Blue Water Ventures International | January 20, 2022

Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...

Read More